See the DrugPatentWatch profile for methotrexate

After reviewing the available information, it is recommended that elderly patients should receive lower doses of methotrexate due to the potential for increased drug toxicity in this population [1]. Methotrexate is an immunosuppressive drug commonly used to treat various conditions such as rheumatoid arthritis, psoriasis, and certain types of cancer [1]. However, elderly patients may experience increased drug toxicity due to age-related physiological changes, such as decreased renal function and altered drug metabolism [1].

Reduced methotrexate clearance in elderly patients can lead to increased drug exposure and toxicity, which may manifest as myelosuppression, mucositis, and hepatotoxicity [1]. Therefore, it is crucial to adjust the methotrexate dosage in elderly patients based on their renal function, body weight, and other individual factors [1].

Moreover, it is essential to closely monitor elderly patients receiving methotrexate therapy for signs of toxicity and to adjust the dosage accordingly [1]. Healthcare providers should also educate elderly patients and their caregivers about the potential risks and symptoms of methotrexate toxicity [1].

In summary, based on the available information, it is recommended that elderly patients receive lower doses of methotrexate due to the potential for increased drug toxicity in this population [1]. Close monitoring and dosage adjustments based on individual factors are crucial to ensure safe and effective methotrexate therapy in elderly patients.

Sources:

1. DrugPatentWatch.com. (n.d.). Methotrexate. Retrieved from <https://www.drugpatentwatch.com/drugs/methotrexate>